Endocrine Abstracts

Background: Sulfonylureas (SUs) are known to increase fasting insulin levels in patients with Type 2 Diabetes (T2D) treated with these agents. Whether this increase is related to a greater risk of hypoglycemia has not yet been sufficiently elucidated.Methods: The study included 58 patients with T2D who had been on treatment with SUs, but not insulin, for more than 2 years. Confirmed hypoglycemic episodes during the past year were self-reported by the pat...